Recursion Review 2026: AI-driven drug discovery platform using computer vision and machine

📋 Overview

282 words · 5 min read

Recursion is a clinical-stage biotechnology company that applies artificial intelligence, specifically computer vision and machine learning, to drug discovery. Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion has built one of the largest proprietary biological and chemical datasets in the world. The company's platform generates millions of cellular images daily through automated microscopy, then uses AI models to analyze these images and identify potential drug candidates, understand disease mechanisms, and predict therapeutic efficacy.

In the rapidly growing AI drug discovery market, Recursion competes with companies like Insilico Medicine, BenevolentAI, Atomwise, and Isomorphic Labs (Google DeepMind's drug discovery subsidiary). Recursion differentiates itself through its massive proprietary dataset generated from its own wet lab experiments, rather than relying solely on publicly available biological data. This vertically integrated approach, combining automated biology with AI analysis, gives Recursion a unique competitive advantage in data quality and experimental validation.

The platform's technology stack combines high-throughput biology with deep learning models trained on cellular imaging data. Recursion can rapidly screen thousands of chemical compounds against hundreds of disease models, identifying promising drug candidates in weeks rather than the months or years typical of traditional drug discovery. The company has developed multiple drug candidates currently in clinical trials, demonstrating that its AI-first approach can translate computational predictions into real therapeutic outcomes.

As of 2026, Recursion has partnerships with major pharmaceutical companies including Roche and Bayer, validating its platform's potential. The company went public in 2021 and continues to invest heavily in expanding its dataset, improving its AI models, and advancing its clinical pipeline. Recursion's platform approach means it can pursue drug discovery across multiple therapeutic areas simultaneously, from rare genetic diseases to oncology and infectious diseases.

⚡ Key Features

241 words · 5 min read

Recursion's core technology revolves around its automated phenomics platform, which generates massive amounts of cellular imaging data. The company operates highly automated laboratories where robotic systems prepare biological samples, apply chemical compounds, and capture high-resolution microscopic images of cellular responses. This generates millions of data points daily, creating a proprietary dataset that forms the foundation of Recursion's AI models.

The AI analysis layer uses convolutional neural networks and other deep learning architectures to analyze cellular images and extract meaningful biological signals. The models can identify subtle changes in cell morphology, protein expression, and cellular behavior that indicate a compound's effect on disease processes. This approach enables Recursion to map relationships between diseases, genes, and chemical compounds at a scale impossible with traditional methods.

Recursion's platform includes a comprehensive map of human biology that the company calls the Recursion OS. This computational framework links diseases, genetic targets, and therapeutic compounds through millions of observed relationships. Researchers can query this map to identify unexpected connections between diseases and potential treatments, discover new drug targets, and predict which patients are most likely to respond to specific therapies.

The clinical development pipeline demonstrates the platform's end-to-end capabilities. Recursion uses its AI models to select drug candidates, predict optimal dosing, identify biomarkers for patient selection, and design efficient clinical trials. The company's lead programs span oncology, rare genetic diseases, and infectious diseases, with multiple candidates in Phase 1 and Phase 2 clinical trials as of 2026.

🎯 Use Cases

233 words · 5 min read

Recursion uses its platform to identify novel drug candidates for rare genetic diseases where traditional drug discovery has struggled due to small patient populations and limited biological understanding. The AI analyzes cellular models of rare diseases, screens thousands of compounds, and identifies candidates that normalize disease-associated cellular phenotypes. This approach has yielded clinical candidates for conditions like cerebral cavernous malformation and neurofibromatosis type 2.

A pharmaceutical partner uses Recursion's platform to identify new indications for existing drugs. By screening approved compounds against Recursion's library of disease models, the partner discovers that a drug originally developed for one condition shows unexpected activity against a different disease. This drug repurposing approach dramatically reduces development timelines since the compound's safety profile is already established.

Recursion applies its AI models to understand the mechanisms of complex diseases like fibrosis and neurodegeneration. The platform identifies genetic targets and biological pathways involved in disease progression, generating hypotheses that guide the design of new therapeutic approaches. These insights feed into Recursion's internal pipeline and are shared with pharmaceutical partners through licensing agreements.

The company uses its computational platform to optimize clinical trial design. AI models predict which patient populations are most likely to respond to treatment based on biomarker profiles, enabling smaller and more efficient clinical trials. The platform also monitors emerging clinical data to identify early signals of efficacy or safety concerns, allowing adaptive trial modifications that improve outcomes.

⚠️ Limitations

Recursion's platform is heavily dependent on the quality and relevance of its cellular imaging data. While the dataset is massive, cellular models may not fully capture the complexity of human disease, particularly for conditions involving complex tissue interactions, immune responses, or neurological processes. Drug candidates that show promise in cellular models can still fail in animal studies or human clinical trials due to unforeseen biological complexities.

The company operates in the high-risk, high-reward space of drug development where failure rates are inherently high. Even with AI-optimized candidate selection, clinical trials are expensive and uncertain, and Recursion has yet to bring a drug to market approval. The platform's competitive advantage depends on continued access to proprietary biological data and the ability to maintain AI model performance as biological understanding evolves. Competition from well-funded competitors like Isomorphic Labs and established pharmaceutical companies building internal AI capabilities poses ongoing strategic risk.

💰 Pricing & Value

Recursion does not sell its platform as a commercial software product available for public purchase. The company operates as a biotechnology firm that develops drugs internally and partners with pharmaceutical companies through licensing and collaboration agreements. Partnership deals are negotiated individually and can range from upfront payments of tens of millions to multi-billion-dollar collaboration agreements with milestone payments.

For pharmaceutical companies interested in accessing Recursion's platform capabilities, engagement typically begins through business development discussions. Collaboration structures vary and may include technology licensing, joint research programs, or drug candidate licensing arrangements. Recursion's publicly disclosed partnerships with Roche and Bayer represent multi-hundred-million-dollar collaborations, indicating the scale of investment required to access the platform.

✅ Verdict

Recursion is relevant for pharmaceutical companies, biotech investors, and researchers interested in AI-driven drug discovery. It's not a tool you can sign up for and use directly. Investors interested in the AI drug discovery space should evaluate Recursion as a clinical-stage biotech with a differentiated AI platform. Individual researchers should look for academic collaborations or alternative computational biology tools.